RxDoctor Payments Data

Joseph Rand, MD

Endocrinology, Diabetes & Metabolism · Sarasota, FLNPI 1013991314

Payments from drug & device makers

$332in general payments, 2019–2025

Across 12 payments — averaging $27.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$96
  • Shire North American Group Inc$71
  • Rhythm Pharmaceuticals, Inc.$33
  • Novo Nordisk$25
  • Dexcom, Inc.$23
  • Antares Pharma, Inc.$21
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$32096%
  • Education$124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$332 in reported general payments places this provider in the 15th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$322,302
Medicare patients
603
Services billed
14,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide354$537,738
OzempicSemaglutide278$405,267
TrulicityDulaglutide184$294,760
JardianceEmpagliflozin171$262,219
Tresiba Flextouch U-200Insulin Degludec60$97,990
Tresiba Flextouch U-100Insulin Degludec93$82,000
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog35$61,252
JanuviaSitagliptin Phosphate45$49,717
Lantus SolostarInsulin Glargine,hum.Rec.Anlog183$44,575
FarxigaDapagliflozin Propanediol49$40,834
Novolog FlexpenInsulin Aspart91$34,185
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/717$32,118
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$31,709
Humalog Kwikpen U-100Insulin Lispro95$27,045
Humalog Kwikpen U-200Insulin Lispro13$24,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$12$848,967574 claims
Novo NordiskOzempic, Tresiba$25$428,947289 claims
AbbVieSynthroid$16$10,273107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →